Immunocore Adds GlaxoSmithKline To Its Growing List Of Partners
This article was originally published in The Pink Sheet Daily
Executive Summary
The British biotech has found validation in two recent partnerships for its cancer immunotherapy platform, while gaining the resources to continue developing its lead compound on its own.
You may also be interested in...
Deals Of The Week Gets Better Connected, Dips A Toe In Digital Health
Digital health promises to transform the quality of health care and reduce costs, but it is not quite yet in a position to help out governments and other payers struggling to meet the demands put on their health care systems. Plus, news of deals between AstraZeneca and Roche, MorphoSys and Celgene, Aspen and Merck, and more.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
Zafgen Drops Beloranib, But Its New Focus Raises Doubts
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.